Based on previous studies, non-small-cell lung cancer is associated with increased brain metastases. However, treatment for ALK-positive non-small-cell lung cancer with alectinib is shown to decrease CNS metastases in comparison to the standard chemotherapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.